http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 10:40:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926665.html si-local-file:///var/storage/secattach/20260814/26926665.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926665.html Fri, 14 Aug 2026 10:40:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926665.html si-local-file:///var/storage/secattach/20260814/26926665.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926665.html Fri, 14 Aug 2026 10:40:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925210.html si-local-file:///var/storage/secattach/20260814/26925210.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925210.html Fri, 14 Aug 2026 08:34:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925210.html si-local-file:///var/storage/secattach/20260814/26925210.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925210.html Fri, 14 Aug 2026 08:34:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+10++Filed+by%3A+Barchas+Isaac/26914541.html si-local-file:///var/storage/secattach/20260812/26914541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+10++Filed+by%3A+Barchas+Isaac/26914541.html Wed, 12 Aug 2026 17:47:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+10++Filed+by%3A+Barchas+Isaac/26914541.html si-local-file:///var/storage/secattach/20260812/26914541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+10++Filed+by%3A+Barchas+Isaac/26914541.html Wed, 12 Aug 2026 17:47:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Barchas+Isaac/26911081.html si-local-file:///var/storage/secattach/20260812/26911081.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Barchas+Isaac/26911081.html Wed, 12 Aug 2026 11:40:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Barchas+Isaac/26911081.html si-local-file:///var/storage/secattach/20260812/26911081.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunome+Inc.++++++++++++++++++++++++++Filed+by%3A+Barchas+Isaac/26911081.html Wed, 12 Aug 2026 11:40:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+04++Filed+by%3A+Horn+Kinney/26910791.html si-local-file:///var/storage/secattach/20260812/26910791.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+04++Filed+by%3A+Horn+Kinney/26910791.html Wed, 12 Aug 2026 11:03:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+04++Filed+by%3A+Horn+Kinney/26910791.html si-local-file:///var/storage/secattach/20260812/26910791.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunome+Inc.+++++++++++++For%3A+Aug+04++Filed+by%3A+Horn+Kinney/26910791.html Wed, 12 Aug 2026 11:03:00 -0400 IMNM O.48629524 http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Raised+to+%2438+at+Truist+Securities/26908851.html Truist Securities analyst Supawat Thongthip raised the price target on Immunome Inc. (NASDAQ: IMNM) to $38.00 (from $37.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Immunome+Inc.+%28IMNM%29+PT+Raised+to+%2438+at+Truist+Securities/26908851.html Wed, 12 Aug 2026 07:15:47 -0400 IMNM http://www.streetinsider.com/Earnings/Immunome%2C+Inc.+%28IMNM%29+Reports+Q2+Loss+of+%240.65/26907063.html <p>Immunome, Inc. (NASDAQ: IMNM) reported Q2 EPS of ($0.65), versus ($0.51) reported last year. Revenue for the quarter came in at $0 versus the consensus estimate of $181.82 thousand.</p><p>For earnings history and earnings-related data on Immunome, Inc. (IMNM) <a href="http://www.streetinsider.com/ec_earnings.php?q=IMNM">click here</a>.</p> http://www.streetinsider.com/Earnings/Immunome%2C+Inc.+%28IMNM%29+Reports+Q2+Loss+of+%240.65/26907063.html Tue, 11 Aug 2026 17:16:41 -0400 IMNM http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26906146.html si-local-file:///var/storage/secattach/20260811/26906146.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26906146.html Tue, 11 Aug 2026 16:22:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26906146.html si-local-file:///var/storage/secattach/20260811/26906146.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Immunome+Inc.++++++++++++++++++++++++/26906146.html Tue, 11 Aug 2026 16:22:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Immunome+Inc.+++++++++++++For%3A+Jun+30/26905800.html si-local-file:///var/storage/secattach/20260811/26905800.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Immunome+Inc.+++++++++++++For%3A+Jun+30/26905800.html Tue, 11 Aug 2026 16:11:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Immunome+Inc.+++++++++++++For%3A+Jun+30/26905800.html si-local-file:///var/storage/secattach/20260811/26905800.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Immunome+Inc.+++++++++++++For%3A+Jun+30/26905800.html Tue, 11 Aug 2026 16:11:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Aug+11/26905606.html si-local-file:///var/storage/secattach/20260811/26905606.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Aug+11/26905606.html Tue, 11 Aug 2026 16:06:00 -0400 IMNM O.48629524 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Aug+11/26905606.html si-local-file:///var/storage/secattach/20260811/26905606.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunome+Inc.+++++++++++++For%3A+Aug+11/26905606.html Tue, 11 Aug 2026 16:06:00 -0400 IMNM O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html <ul class="bwlistdisc"> <li> Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors </li> <li> Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints </li> <li> First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload </li> <li> First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html Tue, 11 Aug 2026 16:02:00 -0400 A.31066700 A.50216726 IMNM O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html <ul class="bwlistdisc"> <li> Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors </li> <li> Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints </li> <li> First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload </li> <li> First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html Tue, 11 Aug 2026 16:02:00 -0400 A.31066700 A.50216726 IMNM O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html <ul class="bwlistdisc"> <li> Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors </li> <li> Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints </li> <li> First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload </li> <li> First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html Tue, 11 Aug 2026 16:02:00 -0400 A.31066700 A.50216726 IMNM O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html <ul class="bwlistdisc"> <li> Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors </li> <li> Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints </li> <li> First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload </li> <li> First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html Tue, 11 Aug 2026 16:02:00 -0400 A.31066700 A.50216726 IMNM O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html <ul class="bwlistdisc"> <li> Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors </li> <li> Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints </li> <li> First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload </li> <li> First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html Tue, 11 Aug 2026 16:02:00 -0400 A.31066700 A.50216726 IMNM O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html <ul class="bwlistdisc"> <li> Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors </li> <li> Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints </li> <li> First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload </li> <li> First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand http://www.streetinsider.com/Press+Releases/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html Tue, 11 Aug 2026 16:02:00 -0400 A.31066700 A.50216726 IMNM O.21612337 O.22422661 O.48629524 http://www.streetinsider.com/Business+Wire/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html <ul class="bwlistdisc"> <li> Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors </li> <li> Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improvements across the primary and all key secondary endpoints </li> <li> First patient dosed in June 2026 in Phase 1 trial of IM-1617, a potential first-in-class solid tumor antibody-drug conjugate incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload </li> <li> First patient dosed in July 2026 in Phase 1 trial of IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand http://www.streetinsider.com/Business+Wire/Immunome+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905446.html Tue, 11 Aug 2026 16:02:00 -0400 A.31066700 A.50216726 IMNM O.21612337 O.22422661 O.48629524